Ben Carson, Sr., is a world-renowned neurosurgeon and former Secretary of the U.S. Department of Housing and Urban Development. Galectin Therapeutics has engaged Dr. Carson to increase awareness of the company, including its ongoing Phase 2b/3 NAVIGATE clinical trial in NASH cirrhosis, its continuing research in combination with cancer immunotherapy, and its potential in addressing other fibrotic diseases. Dr. Carson is also assisting in the formation of a scientific advisory committee for Galectin Therapeutics, recruiting potential members of the committee, and identifying potential strategic commercial and academic partners for Galectin.
Dr. Carson became the Director of Pediatric Neurosurgery at the Johns Hopkins Children’s Center in 1984 at age 33, the youngest chief of pediatric neurosurgery in the United States until that time. At his 2013 retirement from medicine, he was professor of neurosurgery, oncology, plastic surgery, and pediatrics at the Johns Hopkins School of Medicine. He holds a B.A. in psychology from Yale University, an M.D. from the University of Michigan Medical School, and numerous honorary degrees and national merit citations, including the Presidential Medal of Freedom.
Dr. Ben Carson on the potential behind Galectin Therapeutics
...that caused me to start looking into [the science behind Galectin Therapeutics], and really seeing that some of the possibilities of being able to inhibit things like the deleterious protein complex like galectin-3, which is significant in so many types of pathologies.... And it seemed like it was something that people really weren't paying a lot of attention to, even though it potentially impacts tens of millions of people.
